OBIO OBIO
Company Profile ↓Company Overview
OBIO (OBIO) is a publicly traded company listed on with a market capitalization of $240.68M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 111.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.30.
Recent Developments
- Dec 2025 Revenue of $33.48M (+1169.2% YoY); net profit $-52.70M.
- Trailing 12 Months Year-on-year growth — revenue +1169.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 111.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 111.62% |
| 1 Year: | 1,169.22% |
Stock Price Performance
| 1 Year: | +57.46% |
| 6 Months: | +3.43% |
| 3 Months: | +5.24% |
| 1 Month: | +6.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.97 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 111.6% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 866.00K | 401.00K | 1.16M | 1.16M | 915.00K | 419.00K | 620.00K | 778.00K | 987.00K | - | 868.00K | 836.00K | 861.00K | 30.92M | 110.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.00K | 46.00K | 49.00K | 51.00K | 32.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 824.00K | 790.00K | 812.00K | 30.87M | 78.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.75M | 20.12M | 21.12M | 24.11M | 22.15M |
| Operating Income | -68.62K | -111.95K | -96.32K | -94.44K | -5.13M | -7.63M | -10.07M | -11.54M | -12.96M | -14.52M | -14.42M | -16.86M | -16.34M | - | -18.92M | -19.33M | -20.31M | 6.75M | -22.08M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.84M | -19.25M | -20.23M | 7.09M | -21.99M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.75M | -19.36M | -20.83M | 6.25M | -20.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -66.21K | -108.00K | -92.33K | -90.41K | -5.73M | -7.85M | -10.28M | -10.94M | -12.05M | -13.32M | -13.46M | -15.98M | -15.43M | - | -18.75M | -19.36M | -20.83M | 6.25M | -20.69M |
| Diluted EPS | - | - | 0.00 | 0.00 | -0.62 | -0.77 | -0.51 | -0.40 | -0.35 | -0.38 | -0.38 | -0.45 | -0.41 | - | -0.49 | -0.50 | -0.40 | - | -0.33 |
| R&D Expense | - | - | - | - | 3.47M | 5.03M | 5.90M | 8.25M | 8.50M | 8.56M | 9.11M | 11.13M | 11.60M | - | 13.48M | 13.85M | 14.03M | - | 15.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | - | 211.00K | 186.00K | 204.00K | 190.00K |
| Gross Profit | - | 3.32M | 2.57M | 2.43M | 33.29M |
| Operating Expenses | - | 35.98M | 54.08M | 66.73M | 85.10M |
| Operating Income | - | -32.66M | -51.51M | -64.30M | -51.81M |
| EBITDA | - | -32.44M | -51.22M | -63.99M | -51.23M |
| Interest Expense | 927.00K | - | - | - | 1.15M |
| Pretax Income | - | -33.61M | -49.12M | -61.02M | -52.70M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -33.61M | -49.12M | -61.02M | -52.70M |
| Diluted EPS | - | -1.06 | -1.48 | -1.66 | -1.11 |
| R&D Expense | - | 21.95M | 33.82M | 42.80M | 58.19M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 162.16M | - | 95.57M | 95.21M | 76.17M | 114.86M |
| Current Assets | - | - | 84.69M | 89.11M | 69.17M | 107.91M |
| Cash & Equivalents | 2.03M | - | 19.78M | 30.56M | 22.26M | 34.69M |
| Inventory | - | - | 276.00K | 146.00K | 173.00K | 310.00K |
| Receivables | - | - | 96.00K | 99.00K | 92.00K | 95.00K |
| Total Liabilities | 5.72M | - | 43.04M | 27.17M | 43.22M | 61.29M |
| Current Liabilities | 118.96K | - | 18.57M | 11.21M | 16.21M | 16.74M |
| Long Term Debt | - | 3.67M | 9.49M | - | 14.29M | 14.27M |
| Total Debt | - | - | 11.87M | 1.69M | 16.53M | 15.96M |
| Total Equity | -3.56M | - | 52.53M | 68.04M | 32.96M | 53.57M |
| Shares Outstanding | - | - | 31.61M | 35.78M | 38.19M | 57.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -29.29M | -46.13M | -50.56M | -48.96M |
| Investing Cash Flow | - | -64.12M | 10.69M | 13.09M | -26.94M |
| Financing Cash Flow | - | 103.26M | 46.22M | 29.17M | 88.33M |
| Capital Expenditure | - | -591.00K | -78.00K | -289.00K | -489.00K |
| Free Cash Flow | - | -29.88M | -46.20M | -50.85M | -49.45M |
| Net Change in Cash | - | 9.85M | 10.78M | -8.30M | 12.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 94.0% | 93.3% | 92.3% | 99.4% |
| Operating Margin % | - | -924.3% | -1,866.2% | -2,437.5% | -154.7% |
| Net Margin % | - | -951.3% | -1,779.7% | -2,313.3% | -157.4% |
| ROE % | - | -64.0% | -72.2% | -185.2% | -98.4% |
| ROCE % | - | -42.4% | -61.3% | -107.2% | -52.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OBIO
Insider Sale: See Remarks of $OBIO Sells 15,000 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQMnd5OUJxVXNYWmVFN2lMN29DclVKQUhKOWhORm9NMjJRb2FYMDVaazZtLTlxWmpUb0hzNG02RnlHcTdqODNSLVFXc0pFeUVFRTBuU2dMX3BUVUFMU0ZvUUtKTUlzdUdKMEdvRklBMjNiX1RteHpLV1JWYzRzalc3cVEtQi03NFN1T0JHVk…
Orchestra BioMed (NASDAQ: OBIO) insider details Rule 144 sales of 45,000 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPOFNKWDJNbFNGQVF4Zm9kV2NiUmI3dDZmQVV6UnMtQ2J0eV9QNzVPc2FHUk5XXzBKSDUyMl9MbHdQbDhqRGxhejV0MG9LYkZ3SFUxbHJGb21QNkViVjBrRU9jM1BJQndVc0c2d2V2bGZmUnh4eGFlUExiSk9sNGxscFZlZEQtYjBtbUlvVW…
Orchestra BioMed (OBIO) Insider Darren Sherman Sells 15,000 Shar - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQc2Z1WHZ2ZUFtb3RGcW9IZDRzMHBJWEhqVVc3V2Ywa3E4WWVURDNIQmhLb3dBZ2dYVzN5N0FTU3JoQTNibkZsM3BtcmQyV0hBckRaOElLYTU1cTZlcnM2VTRiLVRHOU9WbTRrWFZuX3RTR0laeDhuYkJidllBQ0VUY19IZURieEN4TDE1WV…
Price to book forward of Orchestra BioMed Holdings, Inc. – NASDAQ:OBIO - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNXzdmTEFWRkh4T0s4RThlYUdVaHlrQzlweWlsYU9EZTQzdGN0bUJBMzdYRVRpLXlWRUFXUlR5bS0xYVhmcmNaOWplYW5XQjJZSHd2SllGenFMYW9zcFZhNEl5ZEdlZXYxaTBldHNSYzAtYjFVa19LRHRoU2x1dlNaVkVXalVUemZ0czRYS2…
Orchestra BioMed (OBIO) insider sale under 10b5-1 plan on August 3, 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUmoyMjVfMGtxZDFZdURFWjN6Tk1HN1NqVkIyZmx0T25qWlRJYzdTOEptWUVnUFhPaWd5Vy1NQ3YzZ3NBbVFGRFNyZVhKU3o4YXVqNzVlN3YzbzZ6XzlvNFUyZk5QbjZoYTFob3NwSzRkYnN6amdGUnFQVFVQWFFYSk80dklxN0ZkUHpHMW…
OBIO|Orchestra Biomed Holdings Inc|Price:3.980|Chg%:-0.010 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5nNUxfcnRobDBJLVRaUWQ5S3dUYWNmWENYTWdvRXNOQ2Q0c0dyV2xCUkRpc3hva0pGOUEtNmpaWk44RE1qYWhQQk9LbjFOM1Y1cG9kX1NEVUczSmVwZERVd2I3TVJsQlktNk56VHBn?oc=5" target="_blank">OBIO|Orchestra Biom…
OBIO — Frequently Asked Questions
What is the current share price of OBIO?
As of 2026-08-05 17:25 PDT, OBIO trades at $4.22 on NASDAQ/NYSE. Its 52-week range is $2.35 to $5.35.
What is the market capitalisation of OBIO?
OBIO has a market capitalisation of $240.68M on NASDAQ/NYSE.
What is the P/E ratio of OBIO?
OBIO trades at a trailing price-to-earnings (P/E) ratio of -3.80. Its price-to-book (P/B) ratio is 4.49.
What is the return on equity (ROE) of OBIO?
OBIO has a return on equity (ROE) of -98.38%. Its return on capital employed (ROCE) is -52.80%.
Is OBIO a good stock to buy?
This page provides a data-driven analysis of OBIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.